NeutroSpec: profile and news
FDA alerts public about the dangers of an imaging agent that ... Feb 6, 2006
Manufactured by Palatin Technologies Inc., NeutroSpec, a diagnostic imaging agent injected into a patient's bloodstream, has been recalled by the FDA after the ... - Newstarget.com,
Palatin Technologies, Inc. Reports Fiscal Year 2006 Second Quarter ... Feb 9, 2006
ED) and female sexual dysfunction (FSD), and inventory write-downs associated with the suspension of sales and marketing activities related to NeutroSpec(R), a ... - MSN Money
Palatin Technologies, Inc. Reports Fiscal Year 2006 Second Quarter ... Feb 9, 2006
...dysfunction (FSD), and inventory write-downs associated with the suspension of sales and marketing activities related to NeutroSpec®, a radiopharmaceutical ... - Yahoo! News (press release)
Tyco profits rise in first quarter Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. Tyco ... - Northwest Herald,
Tyco profit increases on lower taxes, costs Feb 3, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. The ... - Royal Gazette,
Palatin Technologies, Inc. Reports Fiscal Year 2006 Second Quarter ... 09 Feb 2006
ED) and female sexual dysfunction (FSD), and inventory write-downs associated with the suspension of sales and marketing activities related to NeutroSpec(R), a ... - MSN Money
Tyco profits rise in first quarter Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. Tyco ... - Northwest Herald,
Tyco Posts $807 Mln 1st-Qtr Profit; Lowers Forecast (Update1) Feb 2, 2006
...higher costs. Tyco in December recalled its NeutroSpec radiology imaging agent in the US after it was linked to two deaths. The ... - Bloomberg
Palatin Technologies to Present at the JP Morgan 24th Annual ... Dec 9, 2005
...therapeutics. The Company has one product (NeutroSpec(TM)) on the market and a pipeline of product candidates in development. The ... - PR Newswire (press release),
Warning Issued on NeutroSpec Dec 5, 2005
Technologies and Tyco Healthcare issued a warning to healthcare professionals late last week about a potential health risk associated with the use of NeutroSpec ... - Newsinferno.com,
Palatin Discloses Potential Health Risk With NeutroSpec Dec 2, 2005
NeutroSpec, Palatin's radiolabeled monoclonal antibody product for imaging and diagnosing infections, is marketed and distributed by Palatin's partner ... - Business Online,
Appendicitis-detecting agent linked to two deaths Dec 6, 2005
2 that a contrast agent used to detect appendicitis, NeutroSpec, was implicated in both cases. ... NeutroSpec is approved for use in patients ages 5 and older. ... - myDNA.com,
Reports of Serious and Life-threatening Cardiopulmonary Events ... Dec 5, 2005
...professionals of postmarketing reports of serious and life-threatening cardiopulmonary events following the administration of NeutroSpec (Technetium [99m Tc ... - DG News
Palatin Technologies, Inc. Announces Issuance of Communication to ... Dec 2, 2005
Technologies and Tyco Healthcare Mallinckrodt have informed the healthcare community about a potential health risk associated with the use of NeutroSpec(TM), a ... - PR Newswire (press release),
Tyco warns of health risk Dec 5, 2005
...warned doctors of life-threatening side effects and two deaths among patients tested with the companies’ NeutroSpec radiology imaging agent.The complications ... - Royal Gazette,
Doctors warned on imaging solution after 2 deaths Dec 2, 2005
...intravenous solution used to help diagnose appendicitis have warned healthcare providers of two deaths and other serious events following the use of NeutroSpec ... - Reuters
Contrast Agent for Appendicitis Confirmation Linked to ... Dec 2, 2005
2 - The FDA warned today that NeutroSpec, a contrast agent used to aid the diagnosis of appendicitis, has been linked two deaths from cardiopulmonary failure. ... - MedPage Today,
Business briefs Dec 3, 2005
...warned doctors of life-threatening side effects and two deaths among patients tested with the companies' NeutroSpec radiology imaging agent. ... - NorthJersey.com,
Palatin Technologies, Inc. Reports Fiscal Year 2006 First Quarter ... Nov 8, 2005
141, a drug under development to treat male and female sexual dysfunction, and lower license fees from Mallinckrodt Healthcare related to NeutroSpec(TM), the ... - PR Newswire (press release),
(PRN) - Flow International Announces Final Fiscal 2006 First ... Dec 2, 2005
...[+]. (PRN) - Palatin Technologies, Inc. Announces Issuance of Communication to Healthcare Providers Concerning NeutroSpec ... [+. ... - Bolsamania.com,
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year ... Sep 14, 2005
...(King) related to PT-141, a drug under development to treat male and female sexual dysfunction, and product revenue from NeutroSpec(TM), approved by the FDA in ... - Yahoo! News (press release)
Palatin Technologies to Present at the UBS Global Life Sciences ... Sep 26, 2005
The Company has one product (NeutroSpec(TM)) on the market generating revenue and a pipeline of product opportunities in development. ... - Yahoo! News (press release)
HEALTH BRIEFS Sep 5, 2005
It looked like a classic case of appendicitis, but to be sure, he ran a new test called NeutroSpec, which detects the location of an infection. ... - Fort Worth Star Telegram,
Palatin Technologies to Present at the Thomas Weisel Partners 2005 ... Aug 30, 2005
The Company has one product (NeutroSpec(TM)) on the market generating revenue and a pipeline of product opportunities in development. ... - Yahoo News (press release)
